Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention

BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Doo Sun, Jeong, Myung Ho, Kim, Weon, Rhew, Jay Young, Yum, Ju Hyup, Kim, Ju Han, Cho, Jeong Gwan, Ahn, Young Keun, Park, Jong Chun, Ahn, Byoung Hee, Kim, Sang Hyung, Kang, Jung Chaee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2003
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://www.ncbi.nlm.nih.gov/pubmed/14619381
http://dx.doi.org/10.3904/kjim.2003.18.3.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531627/
https://www.ncbi.nlm.nih.gov/pubmed/14619381
http://dx.doi.org/10.3904/kjim.2003.18.3.129

Ejemplares similares